医保准入：上市即入保，大幅提升药品可及性

Core Insights - The recent inclusion of AbbVie's innovative drug, Risankizumab (brand name: Skyrizi), in the 2025 National Medical Insurance Directory represents a significant breakthrough for Crohn's disease treatment, as it will be reimbursed starting January 1, 2026, reducing the financial burden on patients [1][2][3] Group 1: Disease Overview - Crohn's disease is a chronic inflammatory bowel disease that primarily affects young adults aged 18-35, with symptoms including abdominal pain, diarrhea, and weight loss [1] - The number of Crohn's disease patients in China is increasing at an annual rate of 5%-10%, leading to significant healthcare costs for families [2] Group 2: Treatment Landscape - Risankizumab is the first IL-23 inhibitor specifically targeting moderate to severe active Crohn's disease, with over 40 countries having real-world usage experience for more than three years [2] - The drug has shown impressive efficacy, with mucosal healing effects approximately double that of similar drugs and 85% of patients maintaining clinical remission for two years [2] Group 3: Financial Implications - Prior to its inclusion in the insurance scheme, the high cost of Risankizumab made it a challenging option for many patients, often leading to difficult choices between treatment efficacy and affordability [3] - With the drug now covered by insurance, the out-of-pocket expenses for patients will significantly decrease, making it more accessible and alleviating financial pressure on families [3]